angiotensin-receptor blockers

Browse trials
Matrix  

Candesartanheart failure, in all type of patients vs placebo

by 130% adverse event

Hyperkalaemia by 535% adverse event

Hypotension by 130% adverse event

Cardiovascular death or hospital admission for CHF by 18% suggested

hospitalisation for heart failure by 28% suggested
Candesartan vs ACE inhibitor only

by 91% adverse event

Hyperkalaemia by 387% adverse event

Adverse events by 32% adverse event
Candesartan vs enalapril

all NS
Candesartanheart failure, in patients previously untreated with ACE inhibitors vs placebo

all NS
Candesartanheart failure, in patients already receiving ACE inhibitor vs ACE inhibitor only

by 92% adverse event

Hyperkalaemia by 387% adverse event

Adverse events by 32% adverse event
Candesartanheart failure, in patients intolerant to ACE inhibitors vs placebo

by 130% adverse event

Hyperkalaemia by 535% adverse event

Hypotension by 312% adverse event

Cardiovascular death or hospital admission for CHF by 18% suggested

hospitalisation for heart failure by 28% suggested
Candesartanheart failure, in patients with preserved-LVEF heart failure vs placebo

all NS
Candesartanhypertension, in all diseases requiring ACEi (HF, CHD, HT,...) vs control

all NS
Candesartan vs conventional treatment

stroke (fatal and non fatal) by 27% suggested

Diabetes onset by 61% suggested
Candesartan vs placebo

all NS
Candesartan vs usual care

all NS
Candesartan vs amlodipine

Diabetes onset by 36% suggested
Candesartan vs hydrochlorothiazide

all NS
Candesartanmiscellaneous, in all type of patients vs control

all NS
Candesartan vs conventional treatment

stroke (fatal and non fatal) by 27% suggested

Diabetes onset by 61% suggested
Candesartan vs placebo

all NS
Candesartan vs amlodipine

Diabetes onset by 36% suggested
Candesartan vs hydrochlorothiazide

all NS
Candesartan vs placebo

all NS
Olmesartandiabetes type 2, in all type of patients vs placebo

Cardiovascular death by 312% suggested
Olmesartan vs placebo

Cardiovascular death by 312% suggested
Telmisartanheart failure, in all type of patients vs enalapril

all NS
Telmisartanheart failure, in patients already receiving ACE inhibitor vs enalapril

all NS
Telmisartanhypertension, in all diseases requiring ACEi (HF, CHD, HT,...) vs placebo

all NS
Telmisartan vs Enalapril

all NS
Telmisartan vs Ramipril

all NS
Telmisartanmiscellaneous, in all type of patients vs placebo

cardiovascular events by 8% suggested
Telmisartan vs ramipril

Hypotension by 54% adverse event

Cough by 74% suggested

angiodema by 60% suggested
Telmisartan vs placebo

cardiovascular events by 8% suggested
Telmisartan vs ramipril

Hypotension by 54% adverse event

Cough by 74% suggested

angiodema by 60% suggested
Telmisartanpatients at high risk for cardiovascular events, in patients intolerant to ACE inhibitors vs placebo

all NS
Valsartanacute myocardial infarction, in all type of patients vs ACE inhibitor only

all NS
Valsartan vs Captopril

all NS
Valsartan vs no valsartan

all NS
Valsartan vs placebo

all NS
Valsartan vs ACE inhibitor only

by 401% adverse event

Adverse events by 46% adverse event

hospitalisation for heart failure by 24% suggested
Valsartan vs enalapril

all NS
Valsartan vs Lisinopril

all NS
Valsartanheart failure, in patients already receiving ACE inhibitor vs ACE inhibitor only

by 401% adverse event

Adverse events by 46% adverse event

hospitalisation for heart failure by 24% suggested
Valsartan vs enalapril

all NS
Valsartanheart failure, in patients previously untreated with ACE inhibitors vs placebo

all NS
Valsartan vs Lisinopril

all NS
Valsartanheart failure, in patients with preserved-LVEF heart failure vs no valsartan

all NS
Valsartanhypertension, in all diseases requiring ACEi (HF, CHD, HT,...) vs Captopril

all NS
Irbesartandiabetes type 2, in all type of patients vs placebo

microvascular events by 70% suggested
Irbesartan vs amlodipine

microvascular events by 23% suggested
Irbesartan vs ACE inhibitor only

all NS
Irbesartanheart failure, in patients already receiving ACE inhibitor vs ACE inhibitor only

all NS
Irbesartanheart failure, in patients with preserved-LVEF heart failure vs placebo

all NS
Irbesartanhypertension, in all diseases requiring ACEi (HF, CHD, HT,...) vs placebo

all NS
Irbesartanmiscellaneous, in all type of patients vs placebo

all NS
Losartanacute myocardial infarction, in all type of patients vs Captopril

Cough by 75% suggested

angiodema by 72% suggested

Adverse events by 48% suggested
Losartan vs placebo

microvascular events by 21% suggested
Losartan vs losartan 50mg

Death from any cause or hospitalization for any reason by 10% suggested

hospitalisation for heart failure by 13% suggested
Losartan vs placebo

All cause death by 72% suggested
Losartan vs ACE inhibitor only

all NS
Losartan vs captopril

Cough by 96% suggested

Adverse events by 41% suggested
Losartan vs enalapril

all NS
Losartanheart failure, in patients already receiving ACE inhibitor vs ACE inhibitor only

all NS
Losartan vs enalapril

all NS
Losartanheart failure, in patients previously untreated with ACE inhibitors vs captopril

Cough by 96% suggested

Adverse events by 41% suggested
Losartanhypertension, in all diseases requiring ACEi (HF, CHD, HT,...) vs placebo

Heart failure by 29% suggested
Losartan vs Captopril

all NS
Losartan vs atenolol

lung cancer by 141% adverse event

cardiovascular events by 14% suggested

stroke (fatal and non fatal) by 25% suggested

Diabetes onset by 25% suggested
Losartanmiscellaneous, in all type of patients vs placebo

Heart failure by 29% suggested
Losartan vs atenolol

lung cancer by 141% adverse event

cardiovascular events by 14% suggested

stroke (fatal and non fatal) by 25% suggested

Diabetes onset by 25% suggested
Losartan vs placebo

Heart failure by 29% suggested
Losartan vs atenolol

lung cancer by 141% adverse event

cardiovascular events by 14% suggested

stroke (fatal and non fatal) by 25% suggested

Diabetes onset by 25% suggested
Captoprilhypertension, in all diseases requiring ACEi (HF, CHD, HT,...) vs Captopril

all NS
Ramiprilhypertension, in all diseases requiring ACEi (HF, CHD, HT,...) vs Ramipril

all NS
Ramiprilmiscellaneous, in all type of patients vs ramipril

Hypotension by 175% adverse event

Adverse events leading to treatment discontinuation by 20% adverse event
Ramipril vs telmisartan

Cough by 323% adverse event

Hypotension by 78% adverse event

Adverse events leading to treatment discontinuation by 28% adverse event
Ramipril vs ramipril

Hypotension by 175% adverse event

Adverse events leading to treatment discontinuation by 20% adverse event
Ramipril vs telmisartan

Cough by 323% adverse event

Hypotension by 78% adverse event

Adverse events leading to treatment discontinuation by 28% adverse event

 


- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons